Big Pharma And Psychedelic Medicine—Eli Lilly’s $3.8 Billion Bet

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Eli Lilly's GLP-1 portfolio, pipeline progress and 2026 acquisitions are driving growth despite pricing pressure and rising competition.
24/7 Wall St.

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026. She framed Eli Lilly’s (NYSE: LLY | LLY Price Prediction) acquisition of Atai Beckley as a bet on rewiring the brain rather than merely dampening symptoms.